Kevin D. Shenk
- Molecular Biology top 5%
- Hematology top 1%
- Oncology top 5%
- Genetics top 10%
- Organic Chemistry
- Co-authors
- Mark K. BennettFrancesco ParlatiSusan D. DemoCongcong SunChristopher J. KirkMonette AujayAsher Chanan‐KhanRobert Z. Orlowski
- Topics
- Ubiquitin and proteasome pathways (11 papers)Multiple Myeloma Research and Treatments (7 papers)Peptidase Inhibition and Analysis (6 papers)
- Cited by
- HematologyOncologyMolecular Biology
- Partner nations
- United StatesNorwaySwitzerland
In The Last Decade
Kevin D. Shenk
18 papers receiving 1.8k citations
Hit Papers
Peers
Comparison fields: 5 of 88
- Molecular Biology 1.5k
- Hematology 860
- Oncology 698
- Genetics 135
- Organic Chemistry 128
Countries citing papers authored by Kevin D. Shenk
This map shows the geographic impact of Kevin D. Shenk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kevin D. Shenk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kevin D. Shenk more than expected).
Fields of papers citing papers by Kevin D. Shenk
This network shows the impact of papers produced by Kevin D. Shenk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kevin D. Shenk. The network helps show where Kevin D. Shenk may publish in the future.
Co-authorship network of co-authors of Kevin D. Shenk
This figure shows the co-authorship network connecting the top 25 collaborators of Kevin D. Shenk. A scholar is included among the top collaborators of Kevin D. Shenk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kevin D. Shenk. Kevin D. Shenk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 329 | |
| 2 | 270 | |
| 3 | 13 | |
| 4 | Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasomebreakdown → | 542 |
| 5 | Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myelomabreakdown → | 591 |
| 6 | 1 | |
| 7 | 1 | |
| 8 | 6 | |
| 9 | 2 | |
| 10 | 3 | |
| 11 | 13 | |
| 12 | 6 | |
| 13 | 16 | |
| 14 | 25 | |
| 15 | 22 | |
| 16 | 22 | |
| 17 | 8 | |
| 18 | 7 |
About Kevin D. Shenk
Kevin D. Shenk is a scholar working on Hematology, Biochemistry and Molecular Biology, having authored 18 papers that have together received 1.9k indexed citations. Recurring topics across this work include Ubiquitin and proteasome pathways (11 papers), Multiple Myeloma Research and Treatments (7 papers) and Peptidase Inhibition and Analysis (6 papers). The work is most often cited by research in Hematology (860 citations), Oncology (698 citations) and Molecular Biology (1.5k citations). Kevin D. Shenk has collaborated with scholars based in United States, Norway and Switzerland. Frequent co-authors include Mark K. Bennett, Francesco Parlati, Susan D. Demo, Congcong Sun, Christopher J. Kirk, Monette Aujay, Asher Chanan‐Khan, Robert Z. Orlowski, Fijs W. B. van Leeuwen and Qing Chen. Their work appears in journals such as Blood, Cancer Research and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.